Glenmark Life Sciences Limited (GLS.BO)
INR 1085.8
(0.0%)
INR 1085.8
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 147.61 Million INR | -13.64% |
| 2022 | 170.92 Million INR | 1319.6% |
| 2021 | 12.04 Million INR | 0.0% |
| 2020 | - INR | 0.0% |
| 2019 | - INR | 0.0% |
| 2018 | - INR | 0.0% |
| 2017 | - INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2024 Q2 | - INR | 0.0% |
| 2023 Q2 | 159.93 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 147.61 Million INR | -13.64% |
| 2023 Q4 | 147.61 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 61 Million INR | 0.0% |
| 2022 FY | 170.92 Million INR | 1319.6% |
| 2022 Q4 | 170.92 Million INR | 0.0% |
| 2021 Q2 | 20.55 Million INR | 0.0% |
| 2021 FY | 12.04 Million INR | 0.0% |
| 2021 Q1 | - INR | 0.0% |
| 2021 Q4 | 12.04 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | 0.0% |
| 2020 Q4 | - INR | 0.0% |
| 2020 Q3 | - INR | 0.0% |
| 2020 FY | - INR | 0.0% |
| 2019 FY | - INR | 0.0% |
| 2018 FY | - INR | 0.0% |
| 2017 FY | - INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 76.525% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.309% |
| Granules India Limited | 689.71 Million INR | 78.598% |
| Indoco Remedies Limited | 3.51 Billion INR | 95.803% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | 37.241% |
| Alkem Laboratories Limited | 400 Million INR | 63.098% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -4040.533% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -430.285% |
| Bajaj HealthCare Limited | 650.34 Million INR | 77.303% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 58.527% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 97.536% |
| Eris Lifesciences Limited | 6.54 Billion INR | 97.745% |
| FDC Limited | 2.46 Million INR | -5885.807% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 90.269% |
| Gufic Biosciences Limited | 1.53 Billion INR | 90.413% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -32.236% |
| Ipca Laboratories Limited | 5.8 Billion INR | 97.457% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -95.329% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 91.956% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 98.284% |
| Lupin Limited | 1.55 Billion INR | 90.494% |
| Mankind Pharma Limited | 248.67 Million INR | 40.642% |
| Medicamen Biotech Limited | 12.55 Million INR | -1075.707% |
| Medico Remedies Limited | 8.67 Million INR | -1602.145% |
| Megasoft Limited | 1.35 Billion INR | 89.123% |
| NATCO Pharma Limited | 53 Million INR | -178.509% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.406% |
| RPG Life Sciences Limited | -30.3 Million INR | 587.162% |
| Sigachi Industries Limited | 265.79 Million INR | 44.465% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -1009.85% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 30.489% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 12209.106% |
| Unichem Laboratories Limited | 382.22 Million INR | 61.381% |
| Wanbury Limited | 820 Million INR | 81.999% |
| Windlas Biotech Limited | 20.18 Million INR | -631.467% |
| ZIM Laboratories Limited | 356 Million INR | 58.537% |
| Zydus Lifesciences Limited | 251 Million INR | 41.191% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -38.471% |
| Divi's Laboratories Limited | 20 Million INR | -638.05% |
| Hester Biosciences Limited | 1.81 Billion INR | 91.879% |
| Procter & Gamble Health Limited | 68.8 Million INR | -114.549% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -956.773% |
| Bal Pharma Limited | 363.82 Million INR | 59.428% |
| Strides Pharma Science Limited | 6.71 Billion INR | 97.802% |
| Venus Remedies Limited | 386.8 Million INR | 61.838% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -36802.5% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 89.48% |
| Shilpa Medicare Limited | 5.6 Billion INR | 97.365% |
| Aarti Drugs Limited | 2.75 Billion INR | 94.639% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 98.538% |
| Valiant Laboratories Limited | 746.63 Million INR | 80.23% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 37.559% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 86.052% |
| Themis Medicare Limited | 267.74 Million INR | 44.868% |
| Hikal Limited | 4.22 Billion INR | 96.509% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.08% |
| Sequent Scientific Limited | 1.42 Billion INR | 89.657% |
| Novartis India Limited | 50.7 Million INR | -191.144% |
| Wockhardt Limited | 8.91 Billion INR | 98.343% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.534% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 67.14% |
| Morepen Laboratories Limited | 33.64 Million INR | -338.793% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -10.535% |